Eagle Asset Management Inc. lowered its position in Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) by 12.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 182,540 shares of the company’s stock after selling 25,992 shares during the period. Eagle Asset Management Inc.’s holdings in Kodiak Sciences were worth $16,236,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its holdings in Kodiak Sciences by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 237,363 shares of the company’s stock worth $20,124,000 after buying an additional 3,936 shares during the period. Ensign Peak Advisors Inc purchased a new stake in Kodiak Sciences in the 4th quarter worth $493,000. Parkwood LLC lifted its stake in Kodiak Sciences by 34.2% in the 4th quarter. Parkwood LLC now owns 8,264 shares of the company’s stock worth $701,000 after purchasing an additional 2,108 shares in the last quarter. Allianz Asset Management GmbH lifted its stake in Kodiak Sciences by 13.2% in the 4th quarter. Allianz Asset Management GmbH now owns 22,266 shares of the company’s stock worth $1,900,000 after purchasing an additional 2,599 shares in the last quarter. Finally, Rafferty Asset Management LLC lifted its stake in Kodiak Sciences by 97.2% in the 4th quarter. Rafferty Asset Management LLC now owns 63,753 shares of the company’s stock worth $5,405,000 after purchasing an additional 31,429 shares in the last quarter. 69.80% of the stock is owned by institutional investors.
Kodiak Sciences stock opened at $6.96 on Friday. Kodiak Sciences Inc. has a 1-year low of $4.90 and a 1-year high of $26.39. The company’s 50-day moving average is $6.89 and its 200 day moving average is $48.27.
Several brokerages have commented on KOD. Roth Capital decreased their price target on shares of Kodiak Sciences from $149.00 to $75.00 in a research note on Monday, February 28th. JPMorgan Chase & Co. cut shares of Kodiak Sciences from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $90.00 to $21.00 in a research note on Thursday, February 24th. Citigroup decreased their price target on shares of Kodiak Sciences from $70.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, February 24th. Chardan Capital restated a “buy” rating on shares of Kodiak Sciences in a research report on Monday, April 11th. Finally, Barclays decreased their target price on shares of Kodiak Sciences from $81.00 to $50.00 and set an “underweight” rating on the stock in a research report on Monday, February 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $45.33.
In other Kodiak Sciences news, CEO Victor Perlroth sold 1,000,000 shares of the company’s stock in a transaction dated Thursday, February 24th. The shares were sold at an average price of $9.20, for a total value of $9,200,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Bros. Advisors Lp Baker bought 223,766 shares of the company’s stock in a transaction on Wednesday, May 18th. The stock was bought at an average price of $5.97 per share, for a total transaction of $1,335,883.02. Following the completion of the purchase, the director now directly owns 15,142,074 shares in the company, valued at $90,398,181.78. The disclosure for this purchase can be found here. Corporate insiders own 39.70% of the company’s stock.
Kodiak Sciences Profile (Get Rating)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
- Get a free copy of the StockNews.com research report on Kodiak Sciences (KOD)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.